RESIDUE TRP-48 OF TVA IS CRITICAL FOR VIRAL ENTRY BUT NOT FOR HIGH-AFFINITY BINDING TO THE SU GLYCOPROTEIN OF SUBGROUP-A AVIAN-LEUKOSIS ANDSARCOMA-VIRUSES
K. Zingler et Jat. Young, RESIDUE TRP-48 OF TVA IS CRITICAL FOR VIRAL ENTRY BUT NOT FOR HIGH-AFFINITY BINDING TO THE SU GLYCOPROTEIN OF SUBGROUP-A AVIAN-LEUKOSIS ANDSARCOMA-VIRUSES, Journal of virology, 70(11), 1996, pp. 7510-7516
Previously, mutant Tva receptors were classified as either partially o
r completely defective in mediating subgroup A avian leukosis and sarc
oma virus (ALSV-A) entry (C. Belanger, K. Zingler, and J. A. T. Young,
J. Virol. 69:1019-1024, 1995; K. Zingler, C. Belanger, R. Peters, D.
Agard, and J. A. T. Young, J. Virol. 69:4261-4266, 1995), To specifica
lly test the abilities of these mutant Tva proteins to bind ALSV-A sur
face (SU) protein, binding studies were performed with a subgroup A SU
-immunoadhesin, This fusion protein is composed of the subgroup A Schm
idt-Ruppin SU protein fused in frame to a rabbit immunoglobulin consta
nt region, This reagent was conjugated to fluorescein isothiocyanate a
nd used for flow cytometric analysis with transfected human 293 cells
expressing different forms of Tva. The SU immunoadhesin bound the wild
-type Tva protein with a K-D of approximately 1.5 nM, Amino acid subst
itutions that reduced viral entry at Asp-46 and at Cys-35 and Cys-50,
which are predicted to form an intrachain disulfide bond in Tva, drast
ically reduced the binding affinity for the SU-immunoadhesin. Thus, th
e effects on viral entry of some mutations could be explained solely b
y changes in the binding affinity for ALSV-A SU, However, this was not
true for other mutations tested, especially those with amino acid sub
stitutions that replaced Trp-48. Compared with the wild-type receptor,
these latter mutations led to approximately 43- to 200-fold reduction
s in viral infectivity but only to approximately 2.5- to 3.4-fold redu
ctions in the binding affinity for the SU-immunoadhesin, These results
support a role for Trp-48 of Tva in mediating steps of viral entry su
bsequent to binding ALSV-A SU.